Nuformix PLC Investor Webinar
04 Novembro 2022 - 4:00AM
RNS Non-Regulatory
TIDMNFX
Nuformix PLC
04 November 2022
REACH
4 November 2022
Nuformix plc
("Nuformix" or the "Company" or the "Group")
Investor Webinar
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce that the Company will be
hosting an online presentation and Q&A session at 5.30 p.m. GMT
on Wednesday 9 November 2022. This session is open to all existing
and prospective shareholders. Those who wish to attend should
register via the following link where they will be provided with
access details:
https://us02web.zoom.us/webinar/register/WN_S2zoC1BuS8KLOVZwAhYHNQ
Participants will have the opportunity to submit questions
during the session, but questions are welcomed in advance and may
be submitted to: nuformix@investor-focus.co.uk
Enquiries:
Nuformix plc
Dr Dan Gooding, Executive Director Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of pre-clinical assets with
potential for significant value and early licensing
opportunities.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUPGBAGUPPGQW
(END) Dow Jones Newswires
November 04, 2022 03:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Nuformix (LSE:NFX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024